^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CCND1 expression

i
Other names: CCND1, BCL1, D11S287E, PRAD1, U21B31, Cyclin D1
Entrez ID:
Related biomarkers:
1d
FGF6 inhibits oral squamous cell carcinoma progression by regulating PI3K/AKT and MAPK pathways. (PubMed, Sci Rep)
With an increase in FGF6 expression in nude mice, the expression of FGFR4, pERK, Cyclin D1, pAKT, BCL2, GPX4, and ACSL4 increased, and the expression of Caspase9 decreased. FGF6 may change the expression of apoptosis-related proteins and proliferation factors by binding to FGFR4 in the PI3K-AKT/MAPK pathway and may inhibit the ferroptosis of OSCC, thereby possibly participating in the process of inhibiting OSCC.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • FGFR4 (Fibroblast growth factor receptor 4) • GPX4 (Glutathione Peroxidase 4) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4)
|
CCND1 expression • FGFR4 expression
6d
HPRT1: a preliminary investigation on its involvement in nasopharyngeal carcinoma. (PubMed, Discov Oncol)
This study preliminarily explored the involvement of HPRT1 in NPC based on some cellular assays in vitro, which may provide evidence for investigating the specific mechanism underlying the effects of HPRT1 in cancers.
Journal
|
CCND1 (Cyclin D1) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCC1 (ATP Binding Cassette Subfamily C Member 1) • MMP9 (Matrix metallopeptidase 9) • HPRT1 (Hypoxanthine Phosphoribosyltransferase 1)
|
CCND1 expression • HPRT1 overexpression
8d
Journal
|
CCND1 (Cyclin D1) • IL10 (Interleukin 10) • CASP3 (Caspase 3) • PCNA (Proliferating cell nuclear antigen) • IL13 (Interleukin 13)
|
CCND1 expression
8d
Preclinical • Journal
|
TP53 (Tumor protein P53) • CCND1 (Cyclin D1) • CASP3 (Caspase 3)
|
CCND1 expression • TP53 expression
10d
GdX inhibits the occurrence and progression of breast cancer by negatively modulating the activity of STAT3. (PubMed, Cancer Biol Ther)
Mechanistically, STAT3 emerged as a downstream target gene of GdX. GdX exerts its inhibitory effects on the initiation and progression of BC by negatively modulating the phosphorylation of STAT3.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • BCL2L1 (BCL2-like 1) • STAT3 (Signal Transducer And Activator Of Transcription 3)
|
MYC expression • CCND1 expression
12d
Unveiling the anti-metastatic activity of monoterpene indole alkaloids targeting MMP9 in cancer cells, with a focus on pharmacokinetic and cellular insights. (PubMed, Mol Cells)
Furthermore, among the MIA compounds lyaloside and 5(S)-5 carbomethoxy strictosidine had low cytotoxicity and regulated cancer-related signaling, including cell migration, cell invasion, epithelial-mesenchymal transition and immune evasion. Our findings demonstrated that the MIAs used in this study have potential anti-metastasis properties that occur via MMP9-mediated regulation of cancer signaling and have the potential to be used therapeutically at safe doses.
PK/PD data • Journal • Metastases
|
EGFR (Epidermal growth factor receptor) • CCND1 (Cyclin D1) • MMP9 (Matrix metallopeptidase 9)
|
CCND1 expression
12d
Unlocking vinpocetine's oncostatic potential in early-stage hepatocellular carcinoma: A new approach to oncogenic modulation by a nootropic drug. (PubMed, PLoS One)
These findings strongly suggest that vinpocetine holds promise as a hepatoprotective agent by targeting a range of oncogenic proteins simultaneously. However, further approaches are needed to validate and establish causal links between our observed effects allowing for a more in-depth exploration of the mechanisms underlying vinpocetine's effects and identifying pivotal determinants of outcomes.
Journal • IO biomarker
|
CCND1 (Cyclin D1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • STAT3 (Signal Transducer And Activator Of Transcription 3) • ICAM1 (Intercellular adhesion molecule 1) • CASP3 (Caspase 3) • TGFB1 (Transforming Growth Factor Beta 1)
|
CCND1 expression
12d
Effects of Down-Regulation of PAK1 on Differentiation and Apoptosis of MPN Cells with MPLW515L Gene Mutation and Survival of 6133/MPL Mice (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
Down-regulation of PAK1 can significantly inhibit the growth of 6133/MPL cells, promote the formation of polyploid DNA, induce 6133/MPL cell apoptosis, and prolong the survival time of 6133/MPL mice.
Preclinical • Journal
|
CCND1 (Cyclin D1) • CCND3 (Cyclin D3) • PAK1 (p21 (RAC1) activated kinase 1)
|
CCND1 expression • MPL W515L
14d
GABA Type A receptors expressed in triple negative breast cancer cells mediate chloride ion flux. (PubMed, Front Pharmacol)
Moreover, this GABAAR mediated Cl- flux can be modulated by pharmacological agents and is decreased in TNBC cells with GABAA β3 subunit knockdown. Further, treatment of TNBC cells with bicuculline, a GABAAR antagonist reduced cell viability in TNBC cells Overall, these results point to an unexplored role of GABAAR mediated Cl- flux in TNBC.
Journal • IO biomarker
|
CCND1 (Cyclin D1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
CCND1 expression
16d
MicroRNA-205-5p inhibits the growth and migration of breast cancer through targeting Wnt/β-catenin co-receptor LRP6 and interacting with lncRNAs. (PubMed, Mol Cell Biochem)
Additionally, miR-205-5p overexpression resulted in decreasing the expression of LRP6 in MCF-7 and MDA-MB-231 cells leading to downregulation of Wnt/β-catenin target genes, c-Myc, cyclin D1, and PPARδ and had various regulatory effects on the expression of lncRNAs MALAT1, NEAT1, SNHG5, and SNHG16. miR-205-5p inhibits the proliferation and migration of breast cancer through diverse mechanisms including targeting LRP6, Wnt/β-catenin pathway, and its regulatory effects on lncRNAs.
Review • Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • SNHG16 (Small Nucleolar RNA Host Gene 16) • SNHG5 (Small Nucleolar RNA Host Gene 5) • MIR205 (MicroRNA 205)
|
CCND1 expression
17d
Effect of Spicatoside a on Anti-Osteosarcoma MG63 Cells through Reactive Oxygen Species Generation and the Inhibition of the PI3K-AKT-mTOR Pathway. (PubMed, Antioxidants (Basel))
N-acetylcysteine (NAC)-induced inhibition of ROS generation reduced SpiA-induced AKT inhibition, apoptotic cell death, and anti-metastatic effects by suppressing cell migration and invasion. Overall, these results highlight the anti-osteosarcoma effect of SpiA by inhibiting the AKT signaling pathway through ROS generation, suggesting that SpiA may be a promising compound for the treatment of human osteosarcoma.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • RPS6KB1 (Ribosomal Protein S6 Kinase B1)
|
CCND1 expression
18d
Expanding the Spectrum of GLI1-rearranged Neoplasms of the Gastrointestinal Tract to Include Monophasic Keratin-positive Epithelial Neoplasms. (PubMed, Am J Surg Pathol)
Diffuse strong nuclear cyclin D1 expression was seen in both cases, and conversely, strong cyclin D1 staining was only seen in 5.4% (4/74) of well-differentiated neuroendocrine tumors tested. These 2 GI tract neoplasms highlight a widened spectrum of GLI1-rearranged tumors, now including monophasic epithelial neoplasms with diffuse keratin expression.
Journal
|
CCND1 (Cyclin D1) • GLI1 (GLI Family Zinc Finger 1) • NCAM1 (Neural cell adhesion molecule 1) • SYP (Synaptophysin)
|
CCND1 expression • NCAM1 expression
19d
A-to-I-edited miR-1251-5p restrains tumor growth and metastasis in lung adenocarcinoma through regulating TCF7-mediated Wnt signaling pathway. (PubMed, Discov Oncol)
Compared with original miR-1251-5p, edited miR-1251-5p has stronger anti-cancer effect on LUAD development through inactivating Wnt signaling pathway by inhibiting TCF7.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • ADAR (Adenosine Deaminase RNA Specific) • TCF7 (Transcription Factor 7)
|
MYC expression • CCND1 expression
21d
Establishment of matched bladder cancer PDX and PDX-derived organoid model and evaluation of anti-tumor efficacy of abemaciclib. (PubMed, Clin Transl Oncol)
Our research provided compelling evidence attesting to the reliability and potential of PDX and PDXO models in the realm of precision medicine. These models are instrumental in identifying patients who are likely to respond favorably to a specific drug treatment.
Journal
|
CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4)
|
CCND1 expression
|
Verzenio (abemaciclib)
21d
WTAP promotes laryngeal carcinoma cell progression by posttranscriptional activation of CTHRC1 in an m6A-YTHDF1-dependent way. (PubMed, Cytotechnology)
Moreover, CTHRC1 overexpression attenuated WTAP knockdown-mediated effects on laryngeal carcinoma cell phenotypes and the expression of β-catenin, C-myc and cyclinD1. Thus, WTAP facilitated CTHRC1 mRNA stability in an m6A-dependent manner to activate the Wnt/β-catenin pathway and promote laryngeal carcinoma cell malignant phenotypes.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • WT1 (WT1 Transcription Factor) • WTAP (WT1 Associated Protein)
|
MYC expression • CCND1 expression
21d
NOSTRIN is involved in benign prostatic hyperplasia via inhibition of proliferation, oxidative stress, and inflammation in prostate epithelial cells. (PubMed, Transl Androl Urol)
NOSTRIN is involved in BPH by inhibiting proliferation, oxidative stress, and inflammation in prostate epithelial cells. These functions may act through the inhibition of NF-κB signaling.
Journal
|
CCND1 (Cyclin D1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CDK4 (Cyclin-dependent kinase 4) • TNFA (Tumor Necrosis Factor-Alpha) • PCNA (Proliferating cell nuclear antigen) • IL1B (Interleukin 1, beta) • NOS2 (Nitric Oxide Synthase 2)
|
CCND1 expression
24d
Enhancing radiosensitivity in osteosarcoma via CDKN2C overexpression: A mechanism involving G1 phase arrest mediated by inhibition of CDK4 expression and Thr172 phosphorylation. (PubMed, Biochem Biophys Res Commun)
Our research results indicate that overexpression of CDKN2C enhances radiosensitivity in osteosarcoma through the induction of G1 phase arrest and subsequent apoptosis. G1 phase arrest is mediated by the suppression of CDK4 expression and Thr172 phosphorylation, which consequently affects the expression of phosphorylated RB at the Ser807/811 sites.
Journal
|
CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CDKN2C (Cyclin Dependent Kinase Inhibitor 2C)
|
CCND1 expression • BAX expression • CCND1 expression + CDK4 expression • CDK6 expression
24d
HKDC1 promotes autophagy and proliferation in pancreatic adenocarcinoma through interaction with PARP1 and poly(ADP-ribosyl)ation. (PubMed, Cell Signal)
HKDC1 plays a critical role in the malignant progression of PAAD by activating autophagy and promoting cell proliferation. Our findings suggest that targeting HKDC1 and its downstream signaling pathways may provide novel strategies for PAAD treatment.
Journal • PARP Biomarker
|
CCND1 (Cyclin D1) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • PCNA (Proliferating cell nuclear antigen)
|
CCND1 expression • PCNA expression
25d
TROP2 Expression and Therapeutic Implications in Cutaneous Squamous Cell Carcinoma: Insights From Immunohistochemical and Functional Analysis. (PubMed, Exp Dermatol)
Knockdown of TROP2 also resulted in decreased expression of vimentin, along with reduced migratory capacity. These findings suggest that TROP2 plays a crucial role in cSCC cell proliferation and migration, and highlight the potential of sacituzumab govitecan as a promising therapeutic option for cSCC.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • VIM (Vimentin) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
TROP2 expression • BCL2 expression • CCND1 expression • VIM expression
|
Trodelvy (sacituzumab govitecan-hziy)
26d
Oncogenic accumulation of cysteine promotes cancer cell proliferation by regulating the translation of D-type cyclins. (PubMed, J Biol Chem)
Similar results were observed in hepatocarcinoma cells treated with erastin, an xCT inhibitor. These findings reveal an unappreciated role of cysteine in regulating the growth of malignant cancer cells and deepen our understanding of the cytotoxic effect of xCT inhibitor to prevent cancer cell proliferation.
Journal
|
CCND1 (Cyclin D1) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1)
|
CCND1 expression
|
erastin
27d
Estimating Anticancer Effects of Yohimbine in DMBA-Induced Oral Carcinogenesis Hamster Model: Utilizing Biochemical and Immunohistochemical Techniques. (PubMed, Cell Biochem Funct)
In conclusion, yohimbine improved the biochemical and immunohistochemical markers of DMBA-induced oral cancer and reverted to near normal values via ameliorating the underlying inflammation and oxidative stress conditions. Our study highlighted the potential of yohimbine as anticancer agent, especially against oral cancer and suggested its possible use as repurposed drug.
Preclinical • Journal
|
CCND1 (Cyclin D1) • IL6 (Interleukin 6) • CYB5A (Cytochrome B5 Type A) • PCNA (Proliferating cell nuclear antigen) • CAT (Catalase)
|
CCND1 expression
27d
Exploring the Mechanism of Centipeda minima in Treating Nasopharyngeal Carcinoma Based on Network Pharmacology. (PubMed, Curr Comput Aided Drug Des)
By conducting a network pharmacology approach, we revealed the main ingredients, key targets, and regulatory pathways of Centipeda minima in the treatment of NPC.
Journal
|
EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CCND1 (Cyclin D1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CASP8 (Caspase 8) • MMP9 (Matrix metallopeptidase 9) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
|
CCND1 expression
27d
Desmoplastic Small Round Cell Tumors: Clinical Presentation, Molecular Characterization, and Therapeutic Approach of Seven Patients. (PubMed, Sarcoma)
Due to Cyclin D1 expression, the CDK4/6 inhibitor palbociclib was applied to four patients. The median therapy duration until disease progression in these patients was 4.5 months (range, 1.5-5 months). So, CCND1 genomic gain and Cyclin D1 expression are common features pointing to cell-cycle deregulation as a possible therapeutic target.
Journal
|
CCND1 (Cyclin D1)
|
CCND1 expression • CCND1 expression + CDK4 expression
|
Ibrance (palbociclib)
27d
Heterogeneous Transcriptional Landscapes in Human Sporadic Parathyroid Gland Tumors. (PubMed, Int J Mol Sci)
In conclusion, PAds display heterogeneous transcriptomic profiles which may contribute to the modulation of clinical and biochemical features. The general downregulated gene expression, characterizing a subgroup of PAds, suggests the tumor cells behave as quiescent resting cells, while the severity of PHPT may be associated with the loss of p73 and the lncRNA-mediated deregulation of histones.
Journal
|
CCND1 (Cyclin D1) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • TP73 (Tumor Protein P73) • CDC73 (Cell Division Cycle 73) • HOXA-AS2 (HOXA Cluster Antisense RNA 2)
|
CCND1 expression • CDKN1B expression
27d
Antitumoral and Antiproliferative Potential of Synthetic Derivatives of Scorpion Peptide IsCT1 in an Oral Cavity Squamous Carcinoma Model. (PubMed, Molecules)
Notably, contrary to the parental IsCT1 peptide, AC-AFPK-IsCT1 did not exhibit hemolytic activity or cytotoxicity towards normal cells. Therefore, AC-AFPK-IsCT1 might be a viable therapeutic option for head and neck cancer treatment.
Journal
|
CCND1 (Cyclin D1) • PCNA (Proliferating cell nuclear antigen)
|
CCND1 expression
29d
Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14). (PubMed, Leukemia)
Overexpression of PAX5 resulted in increased CCND1 expression. These results support the importance of rs9344 G enhancer in increasing CCND1 expression in MM.
Journal
|
CCND1 (Cyclin D1) • PAX5 (Paired Box 5)
|
Chr t(11;14) • CCND1 overexpression • CCND1 expression • Chr t(11;14)(q13;q32) • PAX5 overexpression • CCND1-H
29d
Targeting telomerase with MST-312 leads to downregulation of CCND1, MDM2, MYC, and HSP90AA1 and induce apoptosis in Jurkat cell line. (PubMed, Med Oncol)
The expression levels of all genes, including CCND1, MDM2, MYC, and HSP90AA1, were decreased compared to the control group. The results showed that MST-312 induced dose- and time-dependent apoptosis and downregulated the expression of CCND1, MDM2, MYC, and HSP90AA1in Jurkat cell line.
Preclinical • Journal
|
CCND1 (Cyclin D1) • MDM2 (E3 ubiquitin protein ligase) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
|
MYC expression • CCND1 expression
1m
Application of XBP1s Decoy Oligodeoxynucleotide Attenuates Cancerous Phenotype in Huh-7 Hepatocellular Carcinoma Cells. (PubMed, Cell J)
These findings proposed the potential application of XBP1s-decoy ODN to reduce cancerous phenotypes such as cell proliferation, cell migration and apoptosis induction in the Huh-7 cell line. More experiments on other cell lines and primary cells could validate our results.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDH1 (Cadherin 1) • BAX (BCL2-associated X protein) • MMP9 (Matrix metallopeptidase 9) • XBP1 (X-box-binding protein 1)
|
BCL2 expression • MYC expression • CCND1 expression • CDH1 expression • BAX expression
1m
Profiling mRNA and miRNA expression variations associated with cyclin-dependent kinase pathway in the low-grade luminal early breast cancer. (PubMed, J Appl Genet)
This study demonstrated the novel miRNA-mRNA and miRNA-miRNA interactions, providing new insights into the molecular integration in luminal A and B patients. The authors propose that this research could contribute to introducing valuable biomarkers for luminal cancerous cells.
Journal
|
CCND1 (Cyclin D1) • MIR503 (MicroRNA 503) • E2F1 (E2F transcription factor 1) • MIR449A (MicroRNA 449a)
|
CCND1 expression
1m
Runx2 silencing sensitized human renal cell carcinoma cells to ABT-737 apoptosis. (PubMed, Arch Biochem Biophys)
Since overexpression and prognostic roles of Runx2, activated Akt, Mcl-1, fibronectin, cyclin D1, and β-catenin have been revealed in RCC, it is important to explore the precise mechanisms underlying Runx2 oncogenic effects. Although the linking details between Runx2 and PI3K/Akt have yet to be identified, our findings suggest that Mcl-1 and fibronectin are downstream effectors of Runx2 via a regulatory axis of the PI3K/Akt and their promotion of cell growth, migration, and ABT-737 resistance in RCC cells.
Journal • IO biomarker
|
CCND1 (Cyclin D1) • MCL1 (Myeloid cell leukemia 1) • FN1 (Fibronectin 1) • RUNX2 (RUNX Family Transcription Factor 2)
|
MCL1 expression • CCND1 expression
|
ABT-737
1m
Morphological features and genetic background in ectomesenchymal chondromyxoid tumor: A systematic review. (PubMed, Histol Histopathol)
This study provides a comprehensive summary of the clinicopathological, immunohistochemical, and molecular characteristics of EMCMT, aiding in a more accurate microscopic diagnosis of this rare tumor.
Review • Journal
|
CCND1 (Cyclin D1) • EWSR1 (EWS RNA Binding Protein 1) • NCAM1 (Neural cell adhesion molecule 1) • VIM (Vimentin) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1) • GFAP (Glial Fibrillary Acidic Protein) • RREB1 (Ras Responsive Element Binding Protein 1)
|
CCND1 expression • VIM expression
1m
Elevated origin recognition complex subunit 6 expression promotes non-small cell lung cancer cell growth. (PubMed, Cell Death Dis)
Reduced ORC6 levels, downregulated cyclins, and increased apoptosis were evident in ORC6-silenced NSCLC xenograft tissues. In summary, elevated ORC6 expression promotes NSCLC cell growth.
Journal
|
CCND1 (Cyclin D1) • CCNA2 (Cyclin A2) • CCNB1 (Cyclin B1)
|
CCND1 expression
1m
Role of β-adrenergic signaling and the NLRP3 inflammasome in chronic intermittent hypoxia-induced murine lung cancer progression. (PubMed, Respir Res)
Our study underscores the significant contribution of β-adrenergic signaling and the NLRP3 inflammasome to CIH-induced lung cancer progression. These pathways represent potential therapeutic targets for mitigating the impact of OSA on lung cancer.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CCND1 (Cyclin D1) • KDR (Kinase insert domain receptor) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • CD31 (Platelet and endothelial cell adhesion molecule 1) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
CCND1 expression • KDR expression • CD31 expression
1m
Tuberculous Pleural Effusion-Derived Exosomal miR-130b-3p and miR-423-5p Promote the Proliferation of Lung Cancer Cells via Cyclin D1. (PubMed, Int J Mol Sci)
Inhibitors of miR-130b and miR-423-5p suppressed the promotion of lung cancer by TPE-derived exosomes and reduced the expression of p65 and cyclin D1. These results suggest that TPE-derived exosomal miRNAs can serve as a novel therapeutic target in tuberculous fibrosis-induced lung cancer.
Journal • Pleural effusion
|
CCND1 (Cyclin D1) • MIR423 (MicroRNA 423) • RELA (RELA Proto-Oncogene)
|
CCND1 expression • RELA expression
2ms
Recurrent CLTC::SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissue. (PubMed, Blood)
Finally, a TPM3::NTRK1 fusion or MAP2K1 deletion were detected in 2 children with systemic JXG who experienced spontaneous disease regression. This study advances the molecular understanding of histiocytic neoplasms and may guide diagnostics and clinical management.
Journal
|
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • CCND1 (Cyclin D1) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD163 (CD163 Molecule) • TPM3 (Tropomyosin 3) • MAPK1 (Mitogen-activated protein kinase 1) • SYK (Spleen tyrosine kinase) • CLTC (Clathrin Heavy Chain) • CSF1R (Colony stimulating factor 1 receptor) • MRC1 (Mannose Receptor C-Type 1)
|
BRAF V600E • BRAF V600 • NTRK1 fusion • TPM3-NTRK1 fusion • CCND1 expression • CSF1R fusion • PDGFRB fusion • PDGFRB mutation
2ms
Disulfiram Upgrades the Radiosensitivity of Osteosarcoma by Enhancing Apoptosis and P53-Induced Cell Cycle Arrest. (PubMed, Radiat Res)
Our results document that DSF exerts its radiosensitization effects in vivo and in vitro, and is a valuable radiosensitizing drug option for osteosarcoma. The radiosensitization effect is mainly achieved by activating the apoptotic pathway and promoting cell cycle arrest induced by P53/P21 and CDKN2C after irradiation.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • CDKN2C (Cyclin Dependent Kinase Inhibitor 2C)
|
CCND1 expression • TP53 expression • BAX expression
2ms
Biomarkers and Prognostic Stratification of Squamous Cell Carcinoma of the Oral Cavity in Young Adults: how to personalize therapeutic management? (PubMed, Cancer Epidemiol Biomarkers Prev)
High rate of Neutrophil-to-lymphocyte ratio (NLR) was associated with decreased 5-year disease-specific survival, PDL1 expression correlated with improved OS and recurrence-free survival, presence of Fusobacterium, Mutations in p53, Cyclin D1, and VEGF was associated with reduced OS. Combining these markers in young adult oral cavity SCCs should be used to adapt the intensification of therapy in addition to the TNM classification and minor histo-prognostic factors.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • CCND1 (Cyclin D1)
|
PD-L1 expression • TP53 mutation • CCND1 expression
2ms
Furoxan-piplartine hybrids as effective NO donors and ROS inducers in PC3 cancer cells: design, synthesis, and biological evaluation. (PubMed, RSC Med Chem)
Compounds 7 and 9 modulated the expression profiles of critical regulators of cell cycle, such as CDKN1A (p21), c-MYC, and CCND1 (cyclin D1), as well as induced DNA damage. Overall, tethering the furoxan NO-releasing moiety to the cytotoxic natural product PPT had significant impact on the potential anticancer activity and selectivity of the novel hybrid drug candidates, especially 9, as a result of synergistic effects of both furoxan and PPT's ability to release NO, generate ROS, induce DNA damage, and trigger apoptosis.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
CCND1 expression
2ms
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • PVT1 (Pvt1 Oncogene)
|
MYC expression • CCND1 expression
2ms
Fibrotic liver extracellular matrix induces cancerous phenotype in biomimetic micro-tissues of hepatocellular carcinoma model. (PubMed, Hepatobiliary Pancreat Dis Int)
Our findings suggest a regulatory role for the fibrotic matrix in promoting cancerous phenotype, which could potentially accelerate the progression of malignancy in the liver.
Journal
|
CCND1 (Cyclin D1) • CDH1 (Cadherin 1) • AFP (Alpha-fetoprotein) • ACTA2 (Actin Alpha 2 Smooth Muscle) • VIM (Vimentin) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9) • TWIST1 (Twist Family BHLH Transcription Factor 1) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • HNF1A (HNF1 Homeobox A)
|
CCND1 expression • CDH1 expression
2ms
Does immunohistochemical staining predict mobilization success in multiple myeloma patients? (PubMed, Transfus Apher Sci)
Even though we could not find any predictive value of CD56, c-myc, and cyclin D1 expression on mobilization, c-myc was found to be associated with low OS. Further studies with large and homogenous study population would be more informative.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • NCAM1 (Neural cell adhesion molecule 1)
|
MYC expression • CCND1 expression
|
lenalidomide
2ms
Discovery of flavonoid-containing compound Lupalbigenin as anti-NSCLC cancer agents via suppression of EGFR and ERK1/2 pathway. (PubMed, Bioorg Chem)
Furthermore, our results demonstrated that LB showed potential anti-Ex20ins cancer activity through suppression of the EGFR and ERK1/2 signaling pathway in Ba/F3 cells bearing two to three amino acid insertion mutations. These findings suggested that LB might be valuable for further investigation as a potential candidate in the treatment of associated diseases.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • CCNA2 (Cyclin A2)
|
EGFR mutation • EGFR exon 20 insertion • CCND1 expression • TP53 expression • CDK6 expression • CDKN1B expression